GlassScriptPhysician profile
Joel Alcid
NPI 1114248002
$4,915.70
in general payments reported to CMS, 2019-2025
64 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $586 · 2021: $373 · 2022: $115 · 2023: $949 · 2024: $600 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,378 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,378.48 |
| Education | $183.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $525.06 | 2019-2025 | Erleada, Tecvayli, Talvey |
| Celgene Corporation | $305.52 | 2019-2023 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $298.05 | 2019-2025 | Lynparza, Imfinzi |
| Pfizer INC. | $279.95 | 2019-2025 | |
| Astellas Pharma US INC | $246.69 | 2019-2025 | Xtandi, Padcev, Xospata |
| Lilly USA, LLC | $176.83 | 2019-2024 | Jaypirca |
| Novartis Pharmaceuticals Corporation | $172.14 | 2019-2025 | |
| Caris Mpi, INC. | $167.30 | 2025 | Mi Cancer Seek |
| E.R. Squibb & Sons, L.L.C. | $160.77 | 2019-2025 | Opdivo, Reblozyl |
| Amgen INC. | $160.09 | 2020-2023 | Lumakras |
| Daiichi Sankyo INC. | $159.35 | 2020-2025 | Datroway, Enhertu, Injectafer |
| Jazz Pharmaceuticals INC. | $146.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $129.85 | 2019-2024 | Keytruda, Lynparza |
| Epizyme, INC. | $124.99 | 2021 | |
| Progenics Pharmaceuticals, INC. | $122.58 | 2023 | Pylarify |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Alcid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.